Özcan, M. Et Al. 2021. The Efficacy and Safety of Low-Dose Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: Interim Results of a Phase 4 Study. BLOOD , vol.138, no.Supplement 1 , 1208-1210.

Özcan, M., Cassaday, R. D., Singh, P., Zarzycka, E., Zhang, X., Nègre, E., ... Vandendries, E.(2021). The Efficacy and Safety of Low-Dose Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: Interim Results of a Phase 4 Study. BLOOD , vol.138, no.Supplement 1, 1208-1210.

Özcan, MUHİT Et Al. "The Efficacy and Safety of Low-Dose Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: Interim Results of a Phase 4 Study," BLOOD , vol.138, no.Supplement 1, 1208-1210, 2021

Özcan, MUHİT Et Al. "The Efficacy and Safety of Low-Dose Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: Interim Results of a Phase 4 Study." BLOOD , vol.138, no.Supplement 1, pp.1208-1210, 2021

Özcan, M. Et Al. (2021) . "The Efficacy and Safety of Low-Dose Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: Interim Results of a Phase 4 Study." BLOOD , vol.138, no.Supplement 1, pp.1208-1210.

@article{article, author={MUHİT ÖZCAN Et Al. }, title={The Efficacy and Safety of Low-Dose Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: Interim Results of a Phase 4 Study}, journal={BLOOD}, year=2021, pages={1208-1210} }